International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML
Open Access
- 26 November 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (23) , 6047-6058
Abstract
Early clinical experience with the use of chimeric antigen receptor (CAR) T-cell therapies for patients with acute myeloid leukemia (AML) has been beset by high rates of toxicities and low rates of response. We convened an international workshop with the goal of bringing investigators in the field of AML-directed CAR T-cell therapy together to facilitate discussion of challenges and to brainstorm potential solutions. Based on discussions at the workshop, it was evident that (1) treating and targeting AML with CAR T cells is associated with unique clinical challenges, and (2) variability in clinical trial design, definitions of toxicities, correlative data collection, and reporting methods hinders the field’s ability to compare study outcomes and to develop best practices. Further, details of fundamental CAR T-cell attributes and key correlates of efficacy and toxicity were not uniformly reported in published studies, limiting understanding of barriers to success. These observations led to a concerted team effort in which experts in basic/translational science and clinical investigation from pediatric and adult centers worked together to streamline key attributes of clinical trial design and reporting. Consensus criteria were discussed and agreed upon, leading to the creation of a white paper. These guidelines aim to bolster the overall quality of AML-directed CAR T-cell research, allow for comparisons across trials, and inform the next phase of development of AML-directed CAR T-cell therapies that we hope will improve patient outcomes.Keywords
This publication has 100 references indexed in Scilit:
- CAR-T cell expansion platforms yield distinct T cell differentiation statesCytotherapy, 2024
- Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect stainingCytometry Part A, 2023
- Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasmsPediatric Blood & Cancer, 2023
- Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeTransplantation and Cellular Therapy, 2023
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaCancer Cell, 2022
- Safety switches for adoptive cell therapyCurrent Opinion in Immunology, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Influence of various medium environment to in vitro human T cell cultureIn Vitro Cellular & Developmental Biology - Animal, 2018
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AMLCancer Cell, 2017
- Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteriaCytometry Part B: Clinical Cytometry, 2013